Cognition during active methamphetamine use versus remission

• Published in: Journal of clinical and experimental neuropsychology Vol. 43; no. 6; pp. 599 - 610
• Main Authors: Huckans, Marilyn, Boyd, Stephen, Moncrief, Grant, Hantke, Nathan, Winters, Bethany, Shirley, Kate, Sano, Emily, McCready, Holly, Dennis, Laura, Kohno, Milky, Hoffman, William, Loftis, Jennifer M.
• Format: Journal Article
• Language: English
• Published: England Routledge 01-08-2021
• Subjects: addiction; Adult; Amphetamine-Related Disorders - complications; Cognition; dependence; Executive Function; Humans; Methamphetamine - adverse effects; neuropsychological; Neuropsychological Tests; stimulant; substance use disorder; dependence; substance use disorder; Cognition; stimulant; neuropsychological; addiction
• ISSN: 1380-3395; 1744-411X
• DOI: 10.1080/13803395.2021.1976734

To evaluate whether cognitive performance in adults with active methamphetamine use (MA-ACT) differs from cognitive performance in adults in remission from MA use disorder (MA-REM) and adults without a history of substance use disorder (CTLs).
MA-ACT (n = 36), MA-REM (n = 48), and CTLs (n = 62) completed the Neuropsychological Assessment Battery (NAB).
The MA-ACT group did not perform significantly worse than CTLs on any NAB Index. The MA-REM group performed significantly (p < 0.050) worse than CTLs on the NAB Memory Index. The MA-ACT group performed significantly better than CTLs and the MA-REM group on the Executive Functions Index.
Some cognitive deficits are apparent during remission from MA use, but not during active use; this may result in clinical challenges for adults attempting to maintain recovery and continue with treatment.